Purpose Recent research has found unrealistic optimism (UO) among patient-subjects in early-phase oncology trials. Our aim was to investigate the cognitive and motivational factors that evoke this bias in this context. We expected perceptions of control to be a strong correlate of unrealistic optimism.
Methods A study of patient-subjects enrolled in early-phase oncology trials was conducted at two sites in the USA. Respondents completed questionnaires designed to assess unrealistic optimism and several risk attribute variables that have been found to evoke the bias in other contexts.
Results One hundred and seventy-one patient-subjects agreed to be interviewed for our study. Significant levels of perceived controllability were found with respect to all nine research-related questions. Perceptions of control were found to predict unrealistic optimism. Two other risk attribute variables, awareness of indicators (p=0.024) and mental image (p=0.022), were correlated with unrealistic optimism. However, in multivariate regression analysis, awareness and mental image dropped out of the model and perceived controllability was the only factor independently associated with unrealistic optimism (p<0.0001).
Conclusion Patient-subjects reported that they can, at least partially, control the benefits they receive from participating in an early-phase oncology trial. This sense of control may underlie unrealistic optimism about benefiting personally from trial participation. Effective interventions to counteract unrealistic optimism may need to address the psychological factors that give rise to distorted risk/benefit processing.
- early phase cancer trials
- informed consent
- unrealistic optimism
- perceived control
- research ethics
- decision making
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding Work on this study was funded by NIH/NCI grant RO1CA166556.
Competing interests None decalred.
Ethics approval Institutional Review Boards at OHSU and University of Tennessee.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement There are no additional unpublished data.
Read the full text or download the PDF:
Other content recommended for you
- Two concepts of therapeutic optimism
- Understanding people’s ‘unrealistic optimism’ about clinical research participation
- Phase 1 oncology trials and informed consent
- Unrealistic optimism and the ethics of phase I cancer research
- Informed consent for early-phase clinical trials: therapeutic misestimation, unrealistic optimism and appreciation
- Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial
- Smokers’ unrealistic optimism about their risk
- Diabetes causal attributions among affected and unaffected individuals
- Psychological contribution to the understanding of adverse events in health care
- Faith, Hope And (No) Clarity